Jesper Troelsen

AdhesionScore

Stine Bull Jensen

Applicant

Jesper Troelsen

Project description

Colorectal cancer (CRC) is the third most commonly diagnosed malignancy globally, with an annual incidence of approximately 1.9 million new cases. Surgery remains the primary treatment modality for CRC; however, recurrence occurs in up to 30% of cases, which is associated with increased mortality and morbidity. Currently, there is no predictive test for identifying patients at risk of relapse. 

This is what AdhesionScore aims to change with an established, functional cell-based in vitro assay that utilizes pre- and postoperative blood samples from patients to measure the patient's response to surgery by assessing how these blood samples affect cell adhesion. By analyzing the surgical response, AdhesionScore is able to predict the risk of recurrence within 48 hours after the surgery. The aim is to provide cancer surgeons and oncologists with a novel and accurate score that will secure a better follow-up treatment plan and improve patient outcomes by enabling earlier intervention.

Institution

Roskilde University

SPARK information

Jesper and his team were accepted as part of cohort 5.